IO University

LUNG CANCER

Lung cancer is the leading cause of cancer death in the United States and is most often associated with cigarette smoking, though other causes have been identified. Because many people have no symptoms until the disease has metastasized, screening is recommended for groups at higher risk because of older-age and smoking history. Early detection and classification of lung cancer, with staging to guide selection of interventions, can greatly improve patient outcomes. Recent advances in lung cancer treatment include minimally-invasive-surgical and radiofrequency-ablative techniques, targeted therapies, and immunotherapies.

Online modules have been approved for AMA PRA Category 1 Credit(s)™

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Bayer Healthcare, Biocompatibles, Inc., Boston Scientific, Guerbet LLC, and Medical Device Business Services, Inc. (Ethicon).

Click here to access

HEPATOCELLULAR CARCINOMA

Hepatocellular carcinoma (HCC) is a common form of liver cancer that is associated with infection and with hepatitis B and C viruses. Accurate diagnosis and staging allows practitioners to apply the most appropriate treatments including resection, ablation, embolization, systemic therapy, and transplantation.

Online modules have been approved for AMA PRA Category 1 Credit(s)™

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Boston Scientific, BTG International Inc., Guerbet Inc., and Terumo Interventional Systems.

Click here to access

METASTATIC COLORECTAL CANCER

Metastatic colorectal cancer (mCRC) can be managed with a variety of modalities, depending on individual patient factors. This module includes mCRC epidemiology, diagnosis, and staging. It provides an overview of different therapeutic approaches including surgery, chemotherapy, radiotherapy, and integrative approaches.

Online modules have been approved for AMA PRA Category 1 Credit(s)™

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by educational grants from Boston Scientific, BTG International Inc., Guerbet LLC, Healthtronics, and Teurmo Interventional Systems.

Click here to access

LANGUAGE OF ONCOLOGY

The Language of Oncology module is an advanced course designed to provide clinicians including oncologists and interventional radiologists with the tools to be well-versed in Interventional Oncology. This course will examine oncology literature and provide methods for analyzing oncology trials which includes response assessment, clinical trial design, levels of evidence, and endpoint analysis. 

Online modules have been approved for AMA PRA Category 1 Credit(s)™

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Guerbet LLC. 

Click here to access